Pfizer Inc. Website

Pfizer Inc.

NYSE-PFE

Basic

  • Market Cap

    $153.91B

  • EV

    $216.82B

  • Shares Out

    5,662.54M

  • Revenue

    $58.5B

  • Employees

    88,000

Margins

  • Gross

    58.99%

  • EBITDA

    19.69%

  • Operating

    8.99%

  • Pre-Tax

    1.81%

  • Net

    3.62%

  • FCF

    8.19%

Returns (5Yr Avg)

  • ROA

    9.78%

  • ROTA

    43.47%

  • ROE

    23.18%

  • ROCE

    13.76%

  • ROIC

    11.88%

Valuation (TTM)

  • P/E

    —

  • P/B

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

  • EV/Gross Profit

    —

Valuation (NTM)

  • Price Target

    $31.62

  • P/E

    —

  • PEG

    —

  • EV/Sales

    —

  • EV/EBITDA

    —

  • P/FCF

    —

Financial Health

  • Cash

    $12.69B

  • Net Debt

    $62.64B

  • Debt/Equity

    0.84

  • EBIT/Interest

    2.38

Growth (CAGR)

  • Rev 3Yr

    11.99%

  • Rev 5Yr

    7.46%

  • Rev 10Yr

    1.27%

  • Dil EPS 3Yr

    -39.13%

  • Dil EPS 5Yr

    -27.75%

  • Dil EPS 10Yr

    -19.44%

  • Rev Fwd 2Yr

    3.42%

  • EBITDA Fwd 2Yr

    20.56%

  • EPS Fwd 2Yr

    21.71%

  • EPS LT Growth Est

    9.54%

Dividends

  • Yield

    —

  • Payout

    433.67%

  • DPS

    $1.64

  • DPS Growth 3Yr

    2.57%

  • DPS Growth 5Yr

    3.82%

  • DPS Growth 10Yr

    5.5%

  • DPS Growth Fwd 2Yr

    2.67%

Select a metric from the list below to chart it

Dec '14

Dec '15

Dec '16

Dec '17

Dec '18

Dec '19

Dec '20

Dec '21

Dec '22

Dec '23

Dec '24 (E)

Dec '25 (E)

Dec '26 (E)

Metric
Dec '14
Dec '15
Dec '16
Dec '17
Dec '18
Dec '19
Dec '20
Dec '21
Dec '22
Dec '23

Total Revenues

40,905

41,651

81,288

100,330

58,496

Total Revenues % Chg.

0.2%

1.8%

95.2%

23.4%

-41.7%

Cost of Goods Sold, Total

7,847

8,385

30,686

34,097

23,989

Gross Profit

33,058

33,266

50,602

66,233

34,507

Selling General & Admin Expenses, Total

12,766

11,418

9,562

12,200

13,836

R&D Expenses

7,721

8,709

10,360

11,428

10,679

Amortization of Goodwill and Intangible Assets

4,429

3,348

3,700

3,609

4,733

Other Operating Expenses, Total

24,916

23,475

23,622

27,237

29,248

Operating Income

8,142

9,791

26,980

38,996

5,259

Interest Expense, Total

-1,573

-1,449

-1,291

-1,238

-2,209

Interest And Investment Income

445

351

202

565

2,100

Net Interest Expenses

-1,128

-1,098

-1,089

-673

-109

Income (Loss) On Equity Invest.

—

—

—

17

298

471

436

505

Currency Exchange Gains (Loss)

—

—

—

—

-1,153

164

Other Non Operating Income (Expenses)

1,365

1,639

1,904

2,619

1,275

EBT, Excl. Unusual Items

8,396

10,630

28,266

40,225

7,094

Restructuring Charges

-1,093

-837

-1,360

-2,025

-3,331

Merger & Related Restructuring Charges

-2

-58

-92

-200

-668

Gain (Loss) On Sale Of Investments

8,561

557

1,344

-1,273

1,590

Gain (Loss) On Sale Of Assets

32

-237

—

—

222

Asset Writedown

-2,792

-1,691

-86

-421

-3,024

In Process R&D Expenses

—

—

—

—

—

—

-684

-3,469

-953

-194

Legal Settlements

-292

-28

-182

-230

-474

Other Unusual Items

-1,490

-616

-111

-394

-157

EBT, Incl. Unusual Items

11,320

7,036

24,310

34,729

1,058

Income Tax Expense

583

370

1,852

3,328

-1,115

Earnings From Continuing Operations

10,737

6,666

22,458

31,401

2,173

Earnings Of Discontinued Operations

5,318

2,529

-434

6

-15

Minority Interest

-29

-36

-45

-35

-39

Net Income

16,026

9,159

21,979

31,372

2,119

Preferred Dividend and Other Adjustments

1

—

—

—

—

Net Income to Common Incl Extra Items

16,025

9,159

21,979

31,372

2,119

Net Income to Common Excl. Extra Items

10,707

6,630

22,413

31,366

2,134

Total Shares Outstanding

5,534

5,567

5,620

5,616

5,646

Weighted Avg. Shares Outstanding

5,569

5,555

5,601

5,608

5,643

Weighted Avg. Shares Outstanding Dil

5,675

5,632

5,708

5,733

5,709

EPS

2.9

1.6

3.9

5.6

0.4

EPS Diluted

2.8

1.6

3.9

5.5

0.4

EBITDA

13,857

14,455

32,084

44,024

11,517

Effective Tax Rate

5.2%

5.3%

7.6%

9.6%

-105.4%